Summary Gut hormones that modulate the growth of normal pancreas may also modulate the growth of cancers originating from pancreas.
Pancreatic cancer, with its unfavourable properties, remains a challenge to surgical or chemical therapy. Along with the realization that gut hormones not only regulate the secretion but also cell proliferation and differentiation of the exocrine pancreas Longnecker, 1991) , considerable attention has recently been given to the possible hormone responsiveness of pancreatic cancer.
Several studies have focused on the effects of peptides or the status of peptide receptors on the pancreas of animal models. Rats treated with azaserine (inducing the acinar cell tumour) and hamsters treated with BOP [N-nitrosobis(2-oxopropyl)amine; inducing the ductal cell neoplasm] are the most frequently used experimental models to study pancreatic carcinogenesis (Longnecker et al, 1993) . Promotive effects of cholecystokinin (CCK) on the growth of pancreatic neoplasms and overexpression of CCK receptors in pancreatic neoplastic lesions of azaserinetreated rats have been reported by studies from our and other groups (Douglas et al, 1989; Bell et al, 1992; Tang et al, 1995a ). In the BOP-hamster model, however, the effects of CCK on pancreatic carcinogenesis are rather inconsistent (Johnson et al, 1983; Howatson et al, 1985; Meijers et al, 1990) . In addition, the effects of other peptides, such as bombesin (BBS), secretin and vasoactive intestinal peptide (VIP), on the growth of pancreatic cancer in animal models are inconsistent and unclear (Townsend et al, 1981; Poston et al, 1988; Edwards et al, 1989; Meijers et al, 1991 Meijers et al, , 1992 . In the animal models, receptors for BBS, secretin and VIP disappear with the progress of pancreatic carcinogenesis (Tang et al, 1995a (Tang et al, , 1996 . Although the information from the animal models is helpful to understand the biology of pancreatic cancer, the discrepancy of species unavoidably results in vast gaps in the knowledge on human pancreatic cancer.
Human pancreatic adenocarcinoma cell lines are good models for studying the hormone sensitivity of pancreatic cancer. So far, the growth effects of regulatory peptides and the expression of peptide receptors on human pancreatic cancer cell lines are still controversial (Estival et al, 1983; Alexander et al, 1988; Poston et al, 1988; Liehr et al, 1990; Smith et al, 1991; Qin et al, 1994 cancer was used for histological examination, while the other part was rapidly frozen at -80°C. All specimens of the tumours were of well-differentiated ductal pancreatic cancers. Tissue sections (14 jum) were cut at -20°C using a cryostat microtome, mounted onto gelatin-coated slides and dried overnight at -80°C.
Preparation of radioligands ['251 ]Bolton-Hunter sulphated CCK-8 (['25I]BH-CCK-8) and [1251] Tyr4-BBS with a specific activity of 2200 Ci mmol-' were purchased from New England Nuclear, Boston, MA, USA. Tyr-B-ala-secretin and VIP-28 were iodinated using the Chloramine-T oxidation method. lodinated peptides were separated from unincorporated iodide by gel filtration on a Sephadex G25-F or G50-SF column pre-equilibrated with 0.1 N acetic acid and 0.1% gelatin or 0.25 M ammonium hydrogen carbonate (Schaffalitzky et al, 1976; Ensinck et al, 1989 ride, 5 mm magnesium chloride, 1 mM EGTA and 100 pM each radioligand at pH 6.0, 6.5, 7.0 and 7.5 separately for 180 min. Alternate slides were incubated with addition of 1 jiM of the corresponding non-radioactive peptides to determine the extent of nonspecific binding. Specific bindings for CCK, BBS, secretin and VIP were 85%, 75%, 68% and 70%, respectively, of total binding in normal rat pancreas as positive control. The sections were subsequently washed three times for 5 min at 4°C in 50 mm Tris buffer containing 5 g l-1 bovine serum albumin.
Storage phosphor autoradiography studies
After incubation, the dried tissue sections and one slide containing two dried drops of 10 jil of 100 pM labelled peptide for standardization were placed in a storage phosphor cassette for 24 h at 22°C (Tang et al, 1995b) . The latent image stored in the storage phosphor screen was scanned by the Phosphorlmager and the data were processed with ImageQuant software (Molecular Dynamics, Sunnyvale, CA, USA). For standardization in the screen, the average stored radiation energy from the two whole drops of radioligand was quantified and expressed as response value per fmol of labelled peptide. With this standard as reference, response values from incubated tissue sections could be converted to fmol of labelled peptide per area. Besides some sections for binding studies, serial tissue sections with a thickness of 14 jm were homogenized for measurement of the protein content using the Lowry method (Lowry et al, 1951) . Because the area of the sections labelled with radioligands could be determined by storage phosphor autoradiography, the protein content in corresponding sections could be expressed as mg per area in 14-,um-thick tissue sections. Thus, the binding could be converted to fmol of radioligand bound per mg protein (Tang et al, 1995b ).
Determination of CCK receptor subtype
To determine the affinities of various CCK receptor agonists gastrin) and antagonists [devazepide (L364,7 18) and L365,260, obtained from Merck Sharp & Dohme Research Laboratory, Rahway, NJ, USA; lorglumide and CR 2093, gifts from Rotta research laboratories, Milan, Italy] in normal pancreas, dose-inhibition curves were made with the agents indicated above under identical conditions. Binding parameters (Kd, dissociation constant) were determined for each binding site by using a non-linear least-squares curve-fitting program (LIGAND) (Munson et al, 1980) .
RESULTS
Storage phosphor autoradiographs showed specific bindings of secretin to all tumour-free human pancreata (Figure 1 ). With the data from these control pancreatic tissue sections, the dose-inhibition curve was best fit by a one-site model for BBS or secretin. The binding affinities (Kd) of BBS and secretin in control pancreata were 0.5 ± 0.11 and 0.7 ± 0.2 nm respectively. In contrast to tumour-free pancreatic tissue, only 2 of 12 and 5 of 12 pancreatic cancers expressed specific receptors for BBS and secretin respectively. The specific binding amount of labelled BBS or secretin to tissue section of the pancreatic cancers that were receptor positive was similar to that found in control pancreas ( Figure 1 and Table 1 ). No VIP receptors were demonstrable in tumour-free pancreatic tissue. However, VIP receptors were visualized in 3 of 12 pancreatic cancers ( Figure 1 and Table 1 ). As shown in Table 2 , coexistence of BBS and secretin receptors in pancreatic cancer was detected in only one case. In addition, the pancreatic cancer in another case expressed both receptors for VIP and secretin.
No CCK receptors were identified in pancreatic cancers (Figure 1) . However, specific binding of ['251 ]BH-CCK-8 was diffusely distributed through the tissue sections of tumour-free pancreata ( Figure 1 and Table 1) 
DISCUSSION
This study showed that the spectrum of gut peptide receptors in pancreatic adenocarcinoma is different from that in tumour-free pancreas. Receptors for CCK were present in all specimens of control pancreas, while no specific binding of labelled CCK was found in pancreatic cancer. The coexistence of BBS and secretin receptors was present in all tumour-free pancreata but in only one of pancreatic cancer specimens. The histological differentiation of the pancreatic cancer that possessed both BBS and secretin receptors did not differ from that of pancreatic cancers with receptors for BBS or secretin alone or the cancers without receptors for BBS Gut peptide receptors in human pancreatic cancer 1469 or secretin. The reason for the variability in expression of BBS and secretin receptors in pancreatic cancers is unclear. VIP receptors were present in one-fourth of pancreatic cancers, but they were not identified in any of the tumour-free pancreata. This result points out that some pancreatic cancers are associated with an increased VIP receptor expression in the tumours.
On the basis of the affinity for specific CCK antagonists, the receptors for CCK in peripheral tissues can be classified into two subtypes, CCK-A and CCK-B receptors. The CCK-B receptor is identical to gastrin receptor (Wank et al, 1994 (Kumamoto et al, ) ). The existence of a human pancreatic CCK-B receptor has suggested by Northern blot analysis of transcripts prepared i human pancreas, which showed hybridization with a brain c receptor cDNA probe (Silvente-Poirot et al, 1993) . he relatively low affinities of devazepide and lorglumide in the ent radioligand inhibition study indicate the predominance of C-B receptors in the exocrine component of the human ,reas. This finding does not support the implication of in vivo ies (Malesci et al, 1990; Cantor et al, 1991) indicating that the lation of exocrine pancreatic enzyme secretion is mediated by 4-A receptors on acinar cells. Interestingly, the current views eurohormonal regulation of pancreatic exocrine secretion in (1997) 75(10), [1467] [1468] [1469] [1470] [1471] [1472] [1473] . Cancer Research Campaign 1997
Gut peptide receptors in human pancreatic cancer 1471 rats suggest that the actions of gut hormones on the exocrine pancreas in physiological conditions are mediated mainly via either vagal sensory afferent or vagal efferent cholinergic pathways, or a central vagal site (Chey et al, 1995) . The autoradiographic method used in this study allows the identification of receptors on the exocrine pancreas but not on the nerve endings. Therefore, we can not exclude the possible localization of CCK-A receptors on intrapancreatic neurons or nerve fibres of the human pancreas. In adult laboratory animals, rat pancreatic acinar cells contain only CCK-A receptors (Sankaran et al, 1980; Schrenck et al, 1988; Williams et al, 1988; Bell et al, 1992) . The receptors for CCK in the exocrine pancreas of guinea pig or dog (Fourmy et al, 1987; Yu et al, 1987 Yu et al, , 1990 are heterogeneous and present both A and B subtypes. The different characteristics of CCK receptors in pancreata of human and rodent suggest important differences between humans and laboratory animals. However, the predominance of CCK-B receptors is reported in calf pancreas (Meuth et al, 1993) . Therefore, the status of CCK receptor subtype in calf pancreas is closest to that in the human pancreas.
CCK is trophic to the pancreas and stimulates proliferation of rat acinar cell tumours, leading to the speculation that CCK is involved in the development or growth of human pancreatic ductal cell cancer. However, stimulative, inhibitory or no effect of CCK on the growth of human pancreatic cancer cell lines or human pancreatic cancer xenografts in nude mice have been reported (Upp et al, 1987; Smith et al, 1990; Nio et al, 1993) . Although the membrane fractions of some pancreatic cancer cell lines, such as MIA PaCa-2, BxPC-3, Capan-1, MDA-Amp-7 and MDA-Panc-28, expressed CCK-B receptors (Smith et al, 1994) , no specific CCK binding was detected in the membranes of other pancreatic cancer cell lines (Singh et al, 1991) . Moreover, specific CCK binding in intact cells could not be demonstrated (Herrington and Adrian, 1995) . The current study shows an absence of CCK receptors in all the pancreatic cancers studied and therefore does not support the theory of an important role of CCK in ductal pancreatic cancer in humans. This finding may explain the results of a clinical trial that failed to demonstrate any impact of MK-329, a CCK-A receptor antagonist, on tumour progression, pain or nutrition in patients with advanced pancreatic cancer (Abbruzzese et al, 1992) .
Overexpression of CCK receptors in acinar pancreatic adenocarcinoma of azaserine-treated rats have been demonstrated (Bell et al, 1992) . In ductal pancreatic adenocarcinoma of BOP-treated hamsters, however, an absence of CCK receptors was reported in our recent investigation (Tang et al, 1996) . The present study also showed that CCK receptors, consistently present in the tumourfree human pancreas, are not detectable in ductal pancreatic cancer of human. The different histogenesis of pancreatic cancer in rat compared with human and hamster may be responsible for the contrasting results.
The finding that human tumour-free pancreas contained BBS receptors is consistent with a previous in vitro investigation of a single case (Scemama et al, 1986) and provides the molecular basis for the trophic effect of BBS on human pancreas. The role of BBS on pancreatic cancer cell lines is controversial Liehr et al, 1990; Qin et al, 1994) . The comparison of BBS receptors between tumour-free pancreas and pancreatic cancer in the present study does not favour a direct action of BBS on the growth of pancreatic cancer.
Secretin receptors have been identified in human pancreatic membranes (Robberecht et al, 1988) . Recently, Jiang et al (1995) reported molecular cloning and functional expression of a human pancreatic secretin receptor. The current study also demonstrated the presence of secretin receptors in the tissue sections of the control human pancreas. However, less than half of the pancreatic cancers in this study expressed secretin receptors. These variable changes in the status of secretin receptors may help in the understanding of why one group showed no effect of secretin on cell proliferation of pancreatic cancer (Liehr et al, 1990) , whereas another group identified secretin receptors in human pancreatic cancer (Estival et al, 1981) .
In humans, VIP is a secretin-like partial agonist of pancreatic bicarbonate secretion. Data showing that VIP stimulates secretion of insulin, glucagon and bicarbonate output in healthy human subjects (Domschke et al, 1977; Fahrenkrug et al, 1987) indirectly suggest the presence of VIP receptors in the human pancreas. Moreover, mRNA for VIP receptors has been found in the human pancreas (Adamou et al, 1995) . However, demonstration of receptor mRNA does not always reflect the presence of functional receptors in the cell membrane. Furthermore, it is unclear whether mRNA for VIP receptors in the human pancreas is localized in acinar cells, ductal cells, islet cells or nerve fibres. Hitherto, a direct measurement of receptors for VIP on the various components of the normal human pancreas has not been performed. The absence of VIP receptors in the human exocrine pancreas in this study indicates that further investigation on localization of VIP receptors in nerve fibres of the human pancreas would be worthwhile to prove the role of the nervous system in the gut hormone action.
In pancreatic cancer cell lines, such as PANC-1 and MIA PaCa-2, neither specific binding nor effect of VIP were detected Liehr et al, 1990) . However, VIP receptors were identified in another human pancreatic cancer cell line and these receptors were considered to be involved in modulation of the cAMP response during cell proliferation (Estival et al, 1983) . Moreover, in vivo scanning with radioiodinated VIP has visualized tumour masses in patients with pancreatic cancer (Virgolini et al, 1994) . The results of the present study are in agreement with the finding that only some ductal pancreatic adenocarcinomas express VIP receptors.
VIP and secretin are members of the same peptide family. However, they do not share a single receptor when mediating cell functions. Secretin receptors are defined as having a high affinity for secretin and relatively low affinity for VIP. Similarly, the affinity of VIP to its receptors is much higher than that of secretin (Laburthe et al, 1994) . The lack of coexistence of bindings for radioactive secretin and VIP in tumour-free pancreas and in most pancreatic cancers in the current study may indicate that there is no cross-competition between secretin and VIP binding to control or tumour cell membrane receptors.
Although ductal adenocarcinomas of the pancreas constitute a tumour entity, the variable expression of gut peptide receptors in pancreatic cancer suggests biological heterogeneity. The present findings may be important when designing strategies for hormonal therapy of pancreatic cancer.
